More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 1034-1038

  Zhou, Yunlian ^a   Zhang, Yuanyuan ^a   Sheng, Yuanjian ^a   Zhang, Li ^a   Shen, Zheng ^a   Chen, Zhimin ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MACROLIDE; RNA 23S;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL MUTATION; CHILD; CLINICAL FEATURE; FEMALE; GENOTYPE; HOSPITALIZATION; HUMAN; HUMAN TISSUE; LUNG COMPLICATION; MACROLIDE RESISTANT MYCOPLASMA PNEUMONIAE; MACROLIDE SENSITIVE MYCOPLASMA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NASOPHARYNGEAL ASPIRATION; POINT MUTATION; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANEMIA, HEMOLYTIC; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; ENCEPHALITIS; FEMALE; GENES, RRNA; HUMANS; INFANT; INFANT, NEWBORN; MACROLIDES; MALE; MYCOPLASMA PNEUMONIAE; MYOCARDITIS; PNEUMONIA, MYCOPLASMA; POINT MUTATION; RETROSPECTIVE STUDIES; RNA, RIBOSOMAL, 23S; TREATMENT OUTCOME;

EID: 84893479711     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01806-13     Document Type: Article

References (28)

1. Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, Kauppila J, Leinonen M, McCracken GH, Jr. 2004. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 113:701-707. http://dx.doi.org/10.1542/peds.113.4.701.
2. Defilippi A, Silvestri M, Tacchella A, Giacchino R, Melioli G, Di Marco E, Cirillo D, Di Pietro P, Rossi GA. 2008. Epidemiology and clinical features of Mycoplasma pneumoniae infection in children. Resp. Med. 102: 1762-1768. http://dx.doi.org/10.1016/j.rmed.2008.06.022.
3. Socan M, Ravnik I, Bencina D, Dovc P, Zakotnik B, Jazbec J. 2001. Neurological symptoms in patients whose cerebrospinal fluid is cultureand/ or polymerase chain reaction-positive for Mycoplasma pneumoniae. Clin. Infect. Dis. 15;. 32:E31-E35. http://dx.doi.org/10.1086/318446.
4. Azumagawa K, Kambara Y, Murata T, Tamai H. 2008. Four cases of arthritis associated with Mycoplasma pneumoniae infection. Pediatr. Int. 50:511-513. http://dx.doi.org/10.1111/j.1442-200X.2008.02622.x.
5. Hwkins S, Rausch CM, McCanta AC. 2011. Constrictive pericarditis secondary to infection with Mycoplasma pneumoniae. Curr. Opin. Pediatr. 23:126-129. http://dx.doi.org/10.1097/MOP.0b013e328341579c.
6. Metz G, Kraft M. 2010. Effects of atypical infections with Mycoplasma and Chlamydia on asthma. Immunol. Allergy Clin. N. Am. 30:575-585. http://dx.doi.org/10.1016/j.iac.2010.08.003.
7. Radisic M, Torn A, Gutierrez P, Defranchi HA, Pardo P. 2000. Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment. Clin. Infect. Dis. 31:1507-1511. http://dx.doi.org/10.1086/317498.
8. Wang RS, Wang SY, Hsieh KS, Chiou YH, Huang IF, Cheng MF, Chiou CC. 2004. Necrotizing pneumonitis caused by Mycoplasma pneumoniae in pediatric patients: report of five cases and review of literature. Pediatr. Infect. Dis. J. 23:564-567. http://dx.doi.org/10.1097/01.inf.0000130074.56368.4b.
9. Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T. 2008. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J. Infect. 57:223-228. http://dx.doi.org/10.1016/j.jinf.2008.06. 012.
10. Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, Wang M. 2010. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn. Microbiol. Infect. Dis. 67:355-358. http://dx.doi.org/ 10.1016/j.diagmicrobio.2010.03.004.
11. Dumke R, von Baum H, Lück PC, Jacobs E. 2010. Occurrence of macrolideresistant Mycoplasma pneumoniae strains in Germany. Clin. Microbiol. Infect. 16:613-616. http://dx.doi.org/10.1111/j.1469-0691.2009.02968.x.
12. Wolff BJ, Thacker WL, Schwartz SB, Winchell JM. 2008. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob. Agents Chemother. 52:3542-3549. http://dx.doi.org/10.1128/AAC.00582-08.
13. Morozumi M, Hasegawa K, Kobayashi R, Inoue N, Iwata S, Kuroki H, Kawamura N, Nakayama E, Tajima T, Shimizu K, Ubukata K. 2005. Emergence of macrolide-resistant Mycoplasma pneumoniae with a 23S rRNA gene mutation. Antimicrob. Agents Chemother. 49:2302-2306. http://dx.doi.org/10.1128/AAC.49.6. 2302-2306.2005.
14. Kawai Y, Miyashita N, Yamaguchi T, Saitoh A, Kondoh E, Fujimoto H, Teranishi H, Inoue M, Wakabayashi T, Akaike H, Ogita S, Kawasaki K, Terada K, Kishi F, Ouchi K. 2012. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. Respirology 17:354-362. http://dx.doi.org/10.1111/j.1440- 1843.2011.02102.x.
15. Matsubara K, Morozumi M, Okada T, Matsushima T, Komiyama O, Shoji M, Ebihara T, Ubukata K, Sato Y, Akita H, Sunakawa K, Iwata S. 2009. A comparative clinical study of macrolide-sensitive and macrolide resistantMycoplasma pneumoniae infections in pediatric patients. J. Infect. Chemother. 15:380-383. http://dx.doi.org/10.1007/s10156-009-0715-7.
16. Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, Matsuoka M, Kenri T, Arakawa Y, Sasaki T. 2006. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 50:709-712. http://dx.doi.org/10.1128/AAC.50.2.709-712.2006.
17. Nelson S, Belknap SM, Carlson RW, Dale D, Deboisblanc B, Farkas S, Fotheringham N, Ho H, Marrie T, Movahhed H, Root R, Wilson J, CAP Study Group. 1998. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. J. Infect. Dis. 178:1075-1080. http://dx.doi.org/10.1086/515694.
18. Suzuko U, Keisuke S, Hiroyuki E, Kazunobu O, Kenji O, Tomomichi K, Hiroshi S, Hiroyuki T, Tsunekazu H, Toshihiro M, Tsutomu Y. 2011. Japanese guidelines for the management of respiratory infectious diseases in children 2007 with focus on pneumonia. Pediatr. Int. 53:264-276. http://dx.doi.org/10. 1111/j.1442-200X.2010.03316.x.
19. British Thoracic Society of Standards of Care Committee. 2002. BTS guidelines for the community acquired pneumonia in childhood. Thorax 57(Suppl):S1-S34.
20. Hu YM, Jiang ZF. 2002. Zhu futang textbook of pediatrics, 8th ed. People's Medical Publishing House, Beijing, China.
21. Okazaki N, Narita M, Yamada S, Izumikawa K, Umetsu M, Kenri T, Sasaki Y, Arakawa Y, Sasaki T. 2001. Characteristics of macrolideresistant Mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol. Immunol. 45:617-620. http://dx.doi.org/10.1111/j.1348-0421. 2001.tb01293.x.
22. Xin D, Mi Z, Han X, Qin L, Li J, Wei T, Chen X, Ma S, Hou A, Li G, Shi D. 2009. Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China. Antimicrob. Agents Chemother. 53:2158-2159. http://dx.doi.org/10.1128/AAC.01563-08.
23. Cao B, Zhao CJ, Yin YD, Zhao F, Song SF, Bai L, Zhang JZ, Liu YM, Zhang YY, Wang H, Wang C. 2010. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin. Infect. Dis. 51:189-194. http://dx.doi.org/10.1086/ 653535.
24. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, Nakayama E, Sunakawa K, Ubukata K. 2008. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob. Agents Chemother. 52:348-350. http://dx.doi.org/10.1128/AAC.00779- 07.
25. Zhao F, Lv M, Tao X, Huang H, Zhang B, Zhang Z, Zhang J. 2012. Antibiotic sensitivity of 40 Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant isolates from Beijing, China. Antimicrob. Agents Chemother. 56:1108-1109. http://dx.doi.org/10.1128/AAC.05627-11.
26. Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T, Ouchi K, Suzuki I, Andoh T, Kenri T, Sasaki Y, Horino A, Shintani M, Arakawa Y, Sasaki T. 2004. Characterization and molecular analysis of macrolideresistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob. Agents Chemother. 48:4624-4630. http://dx.doi.org/10.1128/AAC.48.12.4624-4630.2004.
27. Narita M, Tanaka H. 2007. Cytokines involved in the severe manifestations of pulmonary diseases caused by Mycoplasma pneumoniae. Pediatr. Pulmonol. 42:397. http://dx.doi.org/10.1002/ppul.20445.
28. Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H, Ohnari S, Chiba N, Iwata S, Ubukata K. 2012. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin. Infect. Dis. 55: 1642-1649. http://dx.doi.org/10. 1093/cid/cis784.